Condition: Cancer · Metastatic Cancer · Sponsor: UMC Utrecht
This phase 1 clinical trial aims to evaluate the safety, tolerability and feasibility of combination treatment of High Intensity Focused Ultrasound Histotripsy (HIFU-HT) and immune checkpoint inhibitors (ICI) in adult patients with metastatic or unresectable cancer that have progressive disease after regular treatment. Patients will undergo one single session of HIFU-HT during treatment with ipilimumab and nivolumab. Safety, tolerability and feasibility endpoints will be studied as well as radiologic, immunologic and clinical response.
This description comes directly from the study's public registry record.
Karijn P.M. Suijkerbuijk, Prof. · +31655234706 · k.suijkerbuijk@umcutrecht.nl
Emma J. van Dijk, M.D. · e.j.vandijk-9@umcutrecht.nl
Always discuss trial participation with your own doctor first.
| University Medical Center Utrecht | Utrecht, Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06524570